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Abstract. The study was carried out on 12 outpatient cats, age between 4 and 16 years, 7 
males and 5 females, that were diagnosed with chronic renal insufficiency. In the first week, 
benazepril was administered orally, in dose of 0,25 mg/kg/day, after that the dose was increased to 0.5 
mg/kg/day. Before and after 1, 4 and 12 weeks of benazepril administration, the blood pressure was 
measured by oscillometric method. For each cat, the systemic blood pressure value was calculated as 
the mean of five consecutive measurements. Blood and urine sample were collected before and after 
four and 12 weeks of the initiation of benazepril administration. After four weeks of benazepril 
administration, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure 
(MAP) and proteinuria, assessed by the urine protein-to-creatinine ratio, were all significantly lower 
(p<0,05) then the values recorded before the administration of benazepril. Benazepril had no 
significant influences concerning the blood biochemical parameters of renal profile.   
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INTRODUCTION 
 
 Chronic renal failure (CRF) is characterized by gradual and irreversible decrease of 
glomerular filtration rate, result of gradual loss of the renal functional mass. In compensation, 
the remaining nephrons suffer structural and functional changes in order to maintain the 
filtration rate constant. The functional adaptation reffers to hyperfiltration, which is produced 
by an increase in the glomerular capillaries blood flow and pressure, following dilatation of 
the afferent arteriole(Verdier-Fontaine and Priymenko, 2003). The glomerular capillary 
pressure can be emphasized by the efferent arteriole constriction, produced by angiotensine II. 
The angiotensine II activity is increased in most of the chronic renal diseases. Increase in the 
glomerular capillary pressure is, in the long run, deleterious to kidney structure and function. 
Elevated pressure leads to proteinuria, increased shear stress and local production of 
cytokines, which cause progressive renal injury.Therefore, decreasing the glomerular 
capillary pressure and consecutive proteinuria are key factors in slowing down the 
progression  to end stage of chronic renal failure (Brown, 2003, Lefebvre and Toutain, 2004) 
Renoprotection can be defined as any dietary or farmacologic intervention to delay 
progression of CRF. The angiotensine converting enzyme inhibitors (ACEI) may lower 
glomerular pressure by decreasing systemic blood pressure and inhibiting the formation of 
angiotensin II which induces vasoconstriction of the efferent arteriole (Lefebvre and Toutain, 
2004). On the available ACE inhibitors, benazepril hydrochloride is different in that is 
excreted in urine and bile. Pharmacokinetic studies showed that in cats, the active metabolite 
of benazepril, benazeprilat, is eliminated principally (approximately 85%) via biliary 
excretion (King et al., 2006). Because of this property, benazepril does not accumulate in the 
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body of animals with renal diseases, indicating its potential as a safe therapeutic means for 
chronic renal failure of small animals (Watanabe and Mishina, 2007; King et al., 2006). 
 The purpose of this study is to evaluate therapeutic effects of benazepril in cats with 
spontaneously occurring chronic renal insufficiency. 
 
  
MATERIALS AND METHODS 
 
 The study was carried out on 12 outpatient cats, age between 4 and 16 years, 7 males 
and 5 females, that were diagnosed with chronic renal insufficiency at Timisoara University 
Veterinary Clinics. Chronic renal failure was diagnosed by physical examination, clinical 
signs and elevated level of serum creatinine. In this study were included cats with serum 
creatinine concentration ≥ 2 mg/dl, that were determined twice before the study to establish 
the diagnosis of renal failure. It is recommended that all cats to be fed a commercial renal 
support diets. 
 In the first week, benazepril was administered orally, in dose of 0,25 mg/kg/day, after 
that, the dose was increased to 0.5 mg/kg/day. Before and after 1, 4 and 12 weeks of 
benazepril administration, the blood pressure was measured using oscillometric blood 
pressure monitor (Cardell Model 9401) that was previously validated for use in dog and cats. 
This automatic oscillometric device indirectly measures systolic blood pressure (SBP), 
diastolic blood pressure (DBP), mean arterial pressure (MAP) and pulse frequency. The 
inflatable cuff was positioned around the forelimb, between the elbow and carpus, at the level 
on the median artery. For each cat, a cuff width of between 30-40% of the limb circumference 
was chosen. Blood pressure was measured in the owner` s presence, after a period of 
acclimatization, before the physical examination, to reduce the magnitude of ”white coat” 
hypertension. For each cat, the systemic blood pressure value was calculated as the mean of 
five consecutive measurements.  
Blood and urine sample were collected before and after 4 and 12 weeks of the initiation of 
benazepril administration. Biochemical blood parameters (creatinine, urea, phosphorus, 
potassium, total protein and albumin) were determined by usualy methods, on Vet-Screen 
biochemical analyzer. Urine  was collected by cystocentesis or urethral catheterization and 
proteinuria was estimated by urine protein to creatinine ratio. Total protein concentration in 
the urine was measured by using a colorimetric pyrogallol red method and urine creatinine 
was determined by Jaffe method. 
The data obtained were analyzed by Mann-Witney test and the differences were 
considered significant at p<0,05. 
 
RESULTS AND DISCUSSIONS 
 
After one week of treatment with benazepril the values of SBP, DBP and MAP were 
lower with 3.94%, 9.08% and 6.85% than initially value (table 1). In the 8th day, the 
benazepril dose was increased to 0.5 mg/kg/day and at the evaluation of 4 weeks, the mean 
values of the SAP, DAP and MAP were lower with 7.23%, 14.28% respectively 11.31% than 
those registered before administration of benazepril. After 12 weeks of treatment with 
benazepril, the blood pressure measured has shown appropriate values with those taken at 4 
weeks (table 1).  
The differences between SBP, DBP and MAP values measured before and after the 
first week of treatment were statistically insignificant (p>0.05). Instead, at 4 and 12 weeks, 
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the values of SBP, DBP and MAP were significantly lower (p<0.05) than the values recorded 
prior of the benazepril administration. The dynamic of the mean values of the blood pressure 
during the treatment with benazepril, in the cats taken in this study, were appropriate with the 
cats with CRF experimentally induced. (Brown et al., 2001; Watanabe and Mishina, 2007) 
Therefore, in the literature there is less data concerning the ACEIs, respectively of benazepril, 
over the blood pressure in cats. 
Table 1. 
Changes in arterial blood pressure prior and during benazepril  
treatment in cats with CRF¹ 
  
During benazepril administration Variable Before benazepril 
administration 1 week 4 weeks 12 weeks 
SBP 
(mmHg) 152,0 ± 12,0 146,0 ±  5,9 141,0 ± 6,9 138,7 ±  5,0 
DBP 
(mmHg) 105,7 ±  13,3 96,1 ±  7,3 90,6 ± 7,5 88,5 ±  5,9 
MAP 
(mmHg) 121,1 ±  12,6 112,8 ±  6,5 107,4 ±  6,3 105,2 ± 3,9 
Pulse 
frequency 135 ±  10,7 136,4 ±  8,2 131,9 ±  12,6 133,5 ±  10,2 
¹ Values are mean ± standard deviation 
 
The most studies were done over the cats CRF surgically induced by ablation of 7/8 of 
total renal masses. The enalapril administrated in dose of 0,5 mg/kg/day for 1 week induced a 
decrease in blood pressure for 15 – 17 hours in cats with polycistic kidney disease, but the 
decrease in systolic blood pressure was only 16 mmHg (Miller et al., 1999). Similarly, in cats 
with experimental renal failure and mild hypertension, treatment with benazepril induced a 
mean decrease of between 5-11% in systolic blood pressure compared with placebo treated 
animals (Brown et al., 2001). Watanabe and Mishina (2007), have obtained a significant 
reduction (value of 10-15% lower) of SBP, DBP and MAP in cats with experimentally 
induced CRF, after one week of treatment with benazepril at doses between 0.92 and 2 
mg/kg/day.  
The effect of the benazepril over the renal function has been appreciated through the 
changes of the blood biochemical parameter of the renal profile. Plasma creatinine 
concentration is an important variable for tolerability assessment in cats with CKD. The mean 
values of the serum creatinine measured at 4 and 12 weeks of treatment with benazepril were 
lower with 10.1% respectively 14%, but the differences were not statistically significant. This 
dynamics of serum creatinine concentration could be explained by the fact that benazepril 
induces a mild decrease of systemic blood pressure and, by the other hand, increases the 
glomerular filtration rate. (Brown et al., 2001) 
The value of serum creatinine obtained in the study of 5 cats with spontaneously CRF 
which have received increasing doses of benazepril (0.25 mg/kg/day in the initial week, 0.5 
mg/kg/day in the second week and 1.0 mg/kg/day in the third week and thereafter) was 
significantly lower since the 12th week compared with cats placebo group. (Watanabe and 
Mishina, 2007) 
The mean values of the serum concentration of urea and phosphate were lower in the 
4th and 12th week of evaluation, but the differences were not significant (p>0.05). During the 
treatment with benazepril, the mean values of serum concentration of total protein, albumine 
and potassium were improved but the differences toward the values prior to benazepril 
administration, were insignificant (p>0.05). 
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In clinical studies made on cats with spontaneously occurring CRF and in 
experimental induced renal failure, no effect on plasma biochemistry and hematology were 
observed following long-term treatment with benazepril. (Brown et al., 2006; King et al., 
2006; Watanabe and Mishina, 2007) 
 
Table 2. 
Blood biochemical parameters and UPC ratio before and during benazepril administration in cats with 
CRF¹  
  
During benazepril administration Variable Before benazepril 
administration 4 weeks 12 weeks 
Creatinine (mg/dl) 2,77 ± 0,73 2,49 ± 0,49 2,39± 0,47 
Urea (mg/dl) 83,0 ± 27,79 74,0 ± 15,92 68,0 ± 15,27 
Albumin (g/dl) 2,90 ± 0,49 2,99 ± 0,41 3,0 ± 0,50 
Total Proteine (g/dl) 7,38 ± 0,63 7,40 ± 0,51 7,34 ± 0,51 
Phosphorus (mg/dl) 5,29 ± 1,93 5,09 ± 1,05 4,78 ± 1,9 
Potasium (mmol/l) 4,11 ± 1,00 4,49 ± 0,64 4,58 ± 0,79 
UPC (mg/dl) 0,42 ± 0,25 0,24 ± 0,13* 0,23 ± 0,13* 
¹ Values are mean ± standard deviation 
* p<0.05 vs. before benazepril adminitration  
 
The urine samples analysis have proved that proteinuria appreciated by UPC ratio was 
the only biochemical variable which has significantly decreased after 4th weeks of benazepril 
treatment (table 2). The evaluation made at 12 weeks showed that the UPC ratios were 
significant decreased compared with those recorded before initiation of benazepril 
administration.  
Proteinuria is not only a marker of glomerular damage, but also a major cause of 
progression of renal failure The data available in cats, reveal an inverse relationship between 
magnitude of proteinuria and survival time in cats with CRF. (Syme et al., 2006; King et al., 
2006; King et al, 2007, Lees et al., 2004). Increased UPC ratio was an independent risk factor 
associated with shorter renal survival time in cats with CRF. (King et al., 2007) Probable 
mechanisms for proteinuria in cats with CRF are glomerular capillary hypertension, systemic 
hypertension or both. (Brown et al., 2001; King et al., 2006; Lefebvre and Toutain, 2004) 
Other causes that can be  involved include incomplete covering of the glomerular surface area 
by podocytes in the presence of glomerular hypertrophy or lesions caused by toxins or 
imunoreactants (Lefebvre and Toutain, 2004).  Reduction of proteinuria with benazepril 
treatment has been reported previously in clinical and experimental study in cats. (King et al, 
2006; Brown et al., 2001) The mechanism of action is attributed to a reduction in filtration 
pressure secondary to reduced glomerular hypertension (Brown et al., 2001). The ACEI may 
lower glomerular pressure by decreasing systemic blood pressure and inhibiting the formation 
of angiotensine II which induces vasoconstriction of the efferent arteriole (Lefebvre and 
Toutain, 2004). This effect has been investigated in cats and dogs with experimental CRF 
using renal micropuncture techniques. In cats, benazepril (0.25 – 2 mg/kg, p.o., q24 h) given 
for approximately 6.5 months induced a decrease in mean glomerular capillary pressure by 12 
– 14 mmHg. The ratio of efferent to afferent arteriolar resistance was decreased by benazepril, 
and the rate of elimination of ultrafiltration was increased about two- to threefold. No 
significant treatment associated changes in single nephron glomerular filtration rate were 
observed. The arteriolar vascular effect of ACEI, and not the systemic hypotensive effect, was 
demonstrated to be the primary factor contributing to the decrease in glomerular hypertension 
(Brown et al., 2001) 
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In a clinical study on cats with spontaneously occurring CRF, the administration of 
benazepril in dose of 0.5 – 1.0 mg/kg/day produced a significant reduction of proteinuria, 
assessed by the urine UPC ratio, and this effect was present in all subgroups tested, including 
cats with UPC<0.2, although the effect was largest in cats with higher UPCs. (King et al., 
2006) 
CONCLUSIONS 
 
 The treatment with benazepril, by decreasing proteinuria and systemic arterial 
hypertension may have favourable effects in treatement of chronic renal insufficiency in cats. 
 Benazepril had no significant influences concerning the blood biochemical parameters 
of renal profile  
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